Loading...

INOVIQ Ltd

IIQ.AX•ASX
HealthcareMedical - Diagnostics & Research
A$0.45
A$0.01(3.45%)

INOVIQ Ltd (IIQ.AX) Stock Overview

Explore INOVIQ Ltd’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
34.39%
↑ 34.39%
Profit Growth
A$-0.06
↑ 26.92%
EPS Growth
A$-0.06
↑ 27.28%
Operating Margin
-510.68%
↑ 24.76%
ROE
-35.86%
↑ 26.92%
Dividend Yield
0.00%
Analyst Recommendations data is not available for IIQ.AXAnalyst Recommendations details for IIQ.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.

CEO

Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S.

Employees

15

Headquarters

23 Normanby Road, Notting Hill, VIC

Founded

1988

Frequently Asked Questions